Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-07
2011-06-07
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S359000, C424S009100
Reexamination Certificate
active
07956035
ABSTRACT:
A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).
REFERENCES:
patent: 5089602 (1992-02-01), Isliker et al.
patent: 5128318 (1992-07-01), Levine et al.
patent: 5652339 (1997-07-01), Lerch et al.
patent: 7053049 (2006-05-01), Luescher et al.
patent: 7361739 (2008-04-01), Bellotti et al.
patent: 2005/0175666 (2005-08-01), Ding
patent: 2006/0205643 (2006-09-01), Cuzzocrea et al.
patent: WO 01/13939 (2001-03-01), None
patent: WO 01/38395 (2001-05-01), None
patent: WO 2006/102395 (2006-09-01), None
Nieuwdorp et al. , Circulation vol. 114, No. 18 Suppl. S. pp. 255 (Oct. 31, 2006).
Young et al., Diabetologia 36, 150-154 (1993).
Cabezas-Cerrato, Diabetologia 41, 1263-1269 (1998).
Alp, N. J., et al., “Tetrahydrobiopterin-dependent preservation of nitric oxide-medicated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression,” The Journal of Clinical Investigation, 112(5): 725-735 (2003).
Balletshofer, B. M., et al., “Intense Cholesterol Lowering Therapy with a HMG-CoA Reductase Inhibitor does not Improve Nictric Oxide Dependent Endothelial Function in type-2 Diabetes A Multicenter, Randomised, Double-Blind, Three-Arm Placebo-Controlled Clinical Trial,” Experimental and Clinical Endocrinology & Diabetes, 113: 324-330 (2005).
Bisoendial R. J., et al., “Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, 25 : e133-e134, (2005), http://www.atvbaha.org.
Bisoendial, R. J., et al., “Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein,” Circulation 107:2944-2948 (2003) http://circ.ahajournals.org.
Brousseau, M. E., et al., “Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol,” The New England Journal of Medicine 350:1505-1515 (2004).
Brownlee, M., “Biochemistry and molecular cell biology of diabetic complications,” Nature 414:813-820 (Dec. 2001).
Cheung, B. M. Y., et al., “Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes,” British Journal of Clinical Pharmacology 57(5):640-651 (2003).
Cockerill, G. W., et al., “High-Density Lipoprotein: Multipotent Effects on Cells of the Vasculature,” International Review of Cytology 188:257-297 (1999).
Colhoun, H. M., et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (Cards): multicentre randomised placebo-controlled trial,” Lancet 364:685-696 (2004).
Dimayuga, P., et al., “Reconstituted HDL Containing Human Apolipoprotein A-1 Reduces VCAM-1 Expression and Neointima Formation Following Periadventitial Cuff-Induced Carotid Injury in apoE Null Mice,” Biochemical and Biophysical Research Communications 264:465-468 (1999).
Du, X., et al., “Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation,” The Journal of Clinical Investigation 116(4): 1071-1080 (Apr. 2006).
Gordon, D. J., et al., “High-Density Lipoprotein Cholesterol and Cardiovascular Disease Four Prospective American Studies,” Circulation 79:8-15 (1989).
Govers, R. et al., “Cellular regulation of endothelial nitric oxide synthase,” Am J. Physiol Renal Physiol 280: F193-F206 (2001).
Haffner, S. M., MD, “Coronary Heart Disease in Patients With Diabetes,” The New England Journal of Medicine, 342(14)1040-1042 (Apr. 6, 2000).
Hedrick C. C., et al., “Glycation impairs high-density lipoprotein function,” Diabetologia, 43:312-320 (2000).
Heitzer, T., et al., “Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus,” Diabetologia 43:1435-1438 (2000).
Keech, A., et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the Field study): randomised controlled trial,” Lancet 366:1849-1861 (2005).
Lerch, P. G., et al., “Production and Characterization of a Reconstituted High Density Lipoprotein for Therapeutic Applications,” Vox Sang 71:155-164 (1996).
Lerch, P. G., et al., “Reconstituted High Density Lipoprotein (rHDL) Modulates Platelet Activity in Vitro and Ex Vivo,” Thromb Haemost 80:316-320 (1998).
Matsunaga, T., et al., “Glycated High-Density Lipoprotein Regulates Reactive Oxygen Species and Reactive Nitrogen Species in Endothelial Cells,” Metabolism 52(1):42-49 (Jan. 2003).
Matz, C. E., et al., “Micellar Complexes of Human Apolipoprotein A-I with Phosphatidylcholines and Cholesterol Prepared from Cholate-Lipid Dispersions,” The Journal of Biological Chemistry 257(8):4535-4540 (Apr. 25, 1982).
Mineo, C., et al., “Endothelial and Antithrombotic Actions of HDL,” Circ Res, 98:1352-1364 (2006).
Mineo, C., et al., “High Density Lipoprotein-induced Endothelial Nitric-oxide Synthase Activation Is Mediated by Akt and MAP Kinases,” The Journal of Biological Chemistry, 278(11):9142-9149 (Mar. 14, 2003).
Moudry, R., et al., “Reconstituted High Density Lipoprotein Modulates Adherence of Polymorphonuclear Leukocytes to Human Endothelial Cells,” Shock, 7(3):175-181 (1997).
Nanjee, M. N., et al., “Acute Effects of Intravenous Infusion of ApoA1/Phosphatidylcholine Discs on Plasma Lipoproteins in Humans,” Arteriosclerosis, Thrombosis, and Vascular Biology 19:979-989 (1999).
Nissen, S. E., et al., “Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial,” JAMA 290(17): 2292-2300 (2003).
Nobécourt, E., et al., “Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia,” Diabetologia 48:529-538 (2005).
Pászty, C., et al., “Apolipoprotein Al Transgene Corrects Apolipoprotein E. Deficiency-induced Atherosclerosis in Mice,” The Journal of Clinical Investigation 94:899-903 (1994).
Pyörälä, K., MD, et al., “Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease,” Diabetes Care 20(4):614-620 (Apr. 1997).
Rohrer, L, et al., “High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease,” Current Opinion in Lipidology 15:269-278 (2004).
Schächinger, V., et al., “Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease,” Circulation, 101:1899-1906 (2000).
Spieker, L. E., et al., “High-Density Lipoprotein Restores Endothelian Function in Hypercholesterolemic Men,” Circulation 105:1399-1402 (2002).
Stroes, E. S. G., et al., “Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication,” Lancet 346:467-471 (1995).
Stroes, E., et al., “Tetrahydrobiopterin Restores Endothelial Function in Hypercholesterolemia,” The Journal of Clinical Investigation 99(1):41-46 (1997).
Takano, S., PhD., et al., “Dual Roles of 5-Hydroxytryptamine in Ischemia-Reperfusion Injury in Isolated Rat Hearts,” J. Cardiovasc Pharmacol Therapeut 9(1):43-50 (2004).
Tangirala, R. K., et al., “Regression of Artherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice,” Circulation 100:1816-
CSL Limited
Foley & Lardner LLP
Kam Chih-Min
LandOfFree
Treatment of endothelial dysfunction in diabetic patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of endothelial dysfunction in diabetic patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of endothelial dysfunction in diabetic patients will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742128